Healthcare Services

Febrile Neutropenia Market to Reach $15.19B by 2030 at 6.1% CAGR

April 21, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Large Will The Febrile Neutropenia Market Be By 2030 Compared To Its 2026 Market Size?

The market for febrile neutropenia has demonstrated substantial expansion in recent years. Its value is forecast to climb from $11.28 billion in 2025 to $11.99 billion by 2026, achieving a compound annual growth rate (CAGR) of 6.3%. This past growth is largely due to factors such as increased cancer chemotherapy usage, a rise in hospital admissions, the widespread availability of broad-spectrum antibiotics, enhanced infection awareness, and the proliferation of oncology centers.

The febrile neutropenia market size is projected to experience significant expansion in the coming years, with its value expected to reach $15.19 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.1%. This projected growth throughout the forecast period can be attributed to advancements in targeted antimicrobial therapy, an increasing oncology patient population, enhanced early infection detection, the rising use of G-CSFs, and the expansion of precision oncology care. Major developments foreseen during this period include a rising incidence of chemotherapy-induced neutropenia, increased application of empirical antibiotic therapy, a growing adoption of supportive care treatments, the expansion of hospital-based infection management systems, and improved diagnostic and monitoring technologies.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/febrile-neutropenia-global-market-report

Which Strong Drivers Are Impacting The Febrile Neutropenia Market Growth?

The expanding occurrence of cancer is projected to fuel the expansion of the febrile neutropenia market moving ahead. Cancer, a complicated set of illnesses, is defined by the unregulated proliferation of aberrant cells capable of invading adjacent tissues and metastasizing throughout the body. The growing rate of cancer is attributed to elements such as an aging demographic, exposure to environmental and occupational hazards, genetic susceptibility, and hormonal alongside reproductive aspects. Febrile neutropenia aids cancer patients by emphasizing the elevated infection risk during chemotherapy, leading to prompt interventions and specific treatments to avert severe complications, consequently enhancing patient results and allowing for uninterrupted cancer therapy. For example, in 2024, data from the Canadian Cancer Society, a national cancer charity situated in Canada, revealed that 32,100 individuals in Canada were diagnosed with lung cancer, making up 23.5% of all cancer fatalities. Significantly, instances of lung cancer among females increased from 15,800 cases in 2023 to 17,300 cases in 2024. Consequently, the expanding occurrence of cancer is stimulating the growth of the febrile neutropenia market.

What Are The Main Segments Within The Febrile Neutropenia Market Segment Structure?

The febrile neutropenia market covered in this report is segmented –

1) By Treatment: Empirical Antibiotic Therapy, Targeted Antibiotic Therapy, Supportive Care

2) By Risk Factors: Chemotherapy-Induced Neutropenia, Transplant-Related Neutropenia, Genetic Disorders

3) By Etiology: Gram-Negative Bacteria, Gram-Positive Bacteria, Fungal Infections, Viral Infections

4) By Diagnostic Methods: Blood Cultures, Imaging Tests, Bone Marrow Aspiration

Subsegments:

1) By Empirical Antibiotic Therapy: Broad-Spectrum Beta-Lactams, Glycopeptides, Carbapenems

2) By Targeted Antibiotic Therapy: Antifungal Therapy, Antiviral Therapy, Gram-Positive Bacterial Therapy, Gram-Negative Bacterial Therapy

3) By Supportive Care: Granulocyte Colony-Stimulating Factors (G-CSFs), Intravenous Fluids, Antipyretics And Pain Management

Which Trends Are Contributing To Changes In The Febrile Neutropenia Market?

Key companies operating in the febrile neutropenia market are concentrating on developing advanced biosimilar drugs, specifically long-acting granulocyte-colony stimulating factor (G-CSF) fusion proteins, to achieve a competitive advantage. These particular fusion G-CSFs are recombinant proteins that link G-CSF to an Fc fragment, thereby enabling sustained neutrophil stimulation over the course of a chemotherapy cycle. For instance, in November 2024, Evive Biotech, a Singapore-based biopharmaceutical company, introduced a non-pegylated long-acting G-CSF in Germany, which is designed for chemotherapy-induced neutropenia. This product provides an extended half-life through an IgG2-Fc fusion and utilizes mammalian cell expression to achieve human-like glycosylation. While these next-generation and biosimilar G-CSFs improve patient access and reduce dosing frequency, they do encounter challenges related to regulatory complexity and potential immunogenicity concerns.

Who Are The Companies Participating In The Febrile Neutropenia Market?

Major companies operating in the febrile neutropenia market are Pfizer Inc., Sanofi S.A., Amgen Inc., Teva Pharmaceutical Industries Ltd., Fresenius Kabi, Aurobindo Pharma Ltd., Lupin Limited, Hospira Inc., Coherus BioSciences Inc., Gennova Biopharmaceuticals Limited, Dr Reddy’s Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Novartis AG, Merck & Co. Inc., AstraZeneca PLC, Bayer AG, Cipla Ltd., Zydus Cadila, Celltrion Inc., Samsung Bioepis Co. Ltd.

Get The Full Febrile Neutropenia Market Report:

https://www.thebusinessresearchcompany.com/report/febrile-neutropenia-global-market-report

Which Region Represents The Largest Share Of The Febrile Neutropenia Market?

North America was the largest region in the febrile neutropenia market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the febrile neutropenia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Febrile Neutropenia Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/febrile-neutropenia-global-market-report

Browse Through More Reports Similar to the Global Febrile Neutropenia Market 2026, By The Business Research Company

Cephalosporin Market Report 2026

https://www.thebusinessresearchcompany.com/report/cephalosporin-global-market-report

Gauchers Disease Market Report 2026

https://www.thebusinessresearchcompany.com/report/gauchers-disease-global-market-report

Lenalidomide Market Report 2026

https://www.thebusinessresearchcompany.com/report/lenalidomide-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795